Stock listing

NASDAQ:GENB Generate Biomedicines, Inc. Stock

Home listing (NASDAQ) of Generate Biomedicines, Inc.

Follow Generate Biomedicines, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:GENB

$9.54 USD -0.84 (-8.1%)

Close on Nov 20, 2026

Since Feb 26, 2026 -40.4% · daily closes, Feb 26, 2026 – Nov 20, 2026, adjusted for splits
Day range
$9.40 – $10.58 USDNov 20, 2026
Volume
967,195 sharesNov 20, 2026
Market cap
$1.22B USDAt the close on Nov 20, 2026 · price × 128.4M shares outstanding
Traded on an average day
$18.61M USDMedian day 1.01M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Generate Biomedicines, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:GENB · Home$9.54 USD-0.84 (-8.1%)967,195$10.06$10.58$9.40$10.38Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GENB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$9.54-0.84-8.1%$10.06$10.58$9.40967,195
$10.38+0.54+5.5%$9.87$10.52$9.681,049,406
$9.84-0.65-6.2%$10.40$10.81$9.73868,031
$10.49-1.58-13.1%$11.90$12.14$10.381,315,499
$12.07-0.50-4.0%$12.64$12.69$11.77797,974
$12.57-0.92-6.8%$12.56$13.33$11.501,608,135
$13.49-0.29-2.1%$14.00$14.00$13.48454,783
$13.78-0.40-2.8%$13.86$14.55$13.60529,861
$14.18+1.12+8.6%$13.25$14.38$12.93666,838
$13.06+0.49+3.9%$12.90$13.17$12.47632,115
$12.57-1.59-11.2%$14.00$14.11$12.461,296,730
$14.16+0.31+2.2%$14.27$14.34$13.40636,267
$13.85+0.64+4.8%$13.33$14.17$13.33723,832
$13.21-1.25-8.6%$14.28$14.64$13.18744,521
$14.46-1.31-8.3%$14.80$15.63$14.251,168,424
$15.77+0.39+2.5%$15.45$16.46$15.321,740,905
$15.38+2.17+16.4%$13.89$15.39$13.713,923,327
$13.21+0.86+7.0%$12.35$13.39$12.20740,237
$12.35-0.06-0.5%$12.52$12.55$12.21340,815
$12.41-0.38-3.0%$12.75$12.94$12.20295,554
$12.79-0.32-2.4%$13.00$13.37$12.54498,911
$13.11+0.21+1.6%$13.04$13.21$12.80421,212
$12.90+0.34+2.7%$12.53$13.07$12.44523,325
$12.56+0.47+3.9%$12.20$12.85$12.12675,260
$12.09-0.97-7.4%$13.02$13.22$11.841,074,700
$13.06+0.54+4.3%$12.53$13.16$12.43974,900
$12.52+0.26+2.1%$12.61$12.90$12.101,951,000
$12.26-1.58-11.4%$13.75$13.75$12.25930,700
$13.84-0.50-3.5%$14.34$14.37$13.81675,900
$14.34+0.35+2.5%$14.06$14.86$13.94903,100
$13.99+0.42+3.1%$13.50$14.14$13.081,155,700
$13.57-0.23-1.7%$13.59$13.99$13.35926,300
$13.80-0.11-0.8%$14.00$14.19$13.551,169,800
$13.91+0.22+1.6%$13.71$14.06$13.451,119,600
$13.69-0.11-0.8%$13.93$14.30$13.301,262,600
$13.80-1.22-8.1%$14.79$14.99$13.771,391,800
$15.02-0.40-2.6%$15.54$15.61$15.00733,200
$15.42+0.51+3.4%$14.90$15.51$14.65594,600
$14.91-0.24-1.6%$15.15$15.32$14.611,135,300
$15.15-0.84-5.3%$16.04$16.10$15.031,266,700
$15.99-0.53-3.2%$16.44$16.48$15.401,438,100
$16.52-0.94-5.4%$17.44$17.59$16.461,424,700
$17.46+0.08+0.5%$17.68$17.97$17.321,306,100
$17.38+0.24+1.4%$17.46$17.68$17.111,393,700
$17.14+0.02+0.1%$17.17$17.30$16.531,402,900
$17.12+1.44+9.2%$16.04$17.83$16.042,204,800
$15.68-0.51-3.2%$16.09$16.40$15.611,509,100
$16.19+0.19+1.2%$15.83$16.27$15.55959,200
$16.00+0.28+1.8%$15.73$16.45$15.391,533,400
$15.72+0.33+2.1%$15.44$15.88$15.32666,000
$15.39-0.13-0.8%$15.32$16.05$15.031,008,300
$15.52-0.38-2.4%$15.80$16.23$15.20977,900
$15.90-0.49-3.0%$16.36$16.36$15.401,257,800
$16.39+0.05+0.3%$16.39$16.62$15.98724,700
$16.34+0.06+0.4%$16.40$16.59$15.97963,900
$16.28+0.49+3.1%$15.75$16.78$15.69892,500
$15.79+0.52+3.4%$15.12$16.01$14.931,048,800
$15.27-0.06-0.4%$15.27$15.63$14.771,551,900
$15.33-0.44-2.8%$15.77$16.30$14.742,353,200
$15.77-0.37-2.3%$17.11$17.47$15.712,856,600
$16.14-4.24-20.8%$20.00$20.14$15.933,850,000
$20.38+2.66+15.0%$17.67$22.67$17.384,692,301
$17.72+1.60+9.9%$16.67$17.99$16.032,500,237
$16.12+0.13+0.8%$16.10$16.70$15.91830,800
$15.99-0.98-5.8%$16.76$16.85$15.74952,700
Ticker
NASDAQ:GENB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Generate Biomedicines, Inc. news

Generate Biomedicines, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
9 in the last 12 months · 9 in all · newest Nov 12, 2026 · oldest 2026
Decks
6 decks · latest October 2026

Where Generate Biomedicines, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:GENB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:GENBBOATSUnited StatesUSD
BX Swiss:GENBBX SwissSwitzerlandCHF
BMV:GENBBMVMexicoMXN

Valuation

EV/sales 28.1× against a median of 15.4×: 4th lowest of 6 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$895.6M USD
P/E
Loss
EV/sales
28.1×
EV/EBITDA
Negative EBITDA
Price/book
3.2×
Gross margin
100.0%
Operating margin
−737.0%
Net margin
−637.0%
Debt to equity
0.2×
Beta vs S&P 500
1.90

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Generate Biomedicines, Inc. · NASDAQ:GENBUS$1.22BUS$895.6Mn/a28.1×n/a3.2×−637.0%0.2×1.90
Avalyn Pharma Inc. · NASDAQ:AVLNUS$1.26BUS$946.4Mn/an/an/a3.4×n/a0.0×0.12
LB Pharmaceuticals Inc · NASDAQ:LBRXUS$1.26BUS$858.7Mn/an/an/a3.0×n/a0.0×0.81
MannKind Corporation · NASDAQ:MNKDUS$1.24BUS$1.46Bn/a3.5×309×n/a−18.1%n/a1.06
Novavax, Inc. · NASDAQ:NVAXUS$1.23BUS$902.3Mn/a2.2×n/an/a−18.6%n/a1.98
Silence Therapeutics PLC · NASDAQ:SLNUS$1.23BUS$984.6Mn/a2,159×n/a5.7×n/a0.0×1.07
Ocular Therapeutix, Inc. · NASDAQ:OCULUS$1.23BUS$774.9Mn/a15.4×n/a2.8×−648.6%0.2×1.35
Taysha Gene Therapies, Inc. · NASDAQ:TSHAUS$1.21BUS$837.4Mn/a153×n/a3.4×n/a0.1×1.69
Mineralys Therapeutics, Inc. · NASDAQ:MLYSUS$1.21BUS$585.1Mn/an/an/a2.4×n/a0.0×1.39
GH Research PLC · NASDAQ:GHRSUS$1.20BUS$841.0Mn/an/an/a3.4×n/a0.0×1.28
Vor Biopharma Inc. · NASDAQ:VORUS$1.18BUS$697.4M0.9×n/an/an/an/an/a1.25
Median of the othersUS$1.23BUS$849.9M0.9×15.4×309×3.4×−18.6%0.0×1.27

Forecasts

4 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
27.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.44 · 4 analysts
Revenue, year to Dec 2026
24.82M · 5 analysts

Team and board

Officers

OfficerRole
Michael NallyChief Executive Officer
Jason SilversPresident & Chief Financial Officer
Sean MartinChief Legal Officer & General Counsel
Daria HazudaSenior Vice President, Discovery Strategy
Dinesh de AlwisSenior Vice President, Head of Clinical Drug Development
Sahm NasseriSenior Vice President, Business Development and Strategy
Aarif KhakooChief Scientific Officer
Beth GrousChief People Officer
Gevorg GrigoryanCo-Founder & Chief Technology Officer
Laurie LeeChief Medical Officer, Immunology & Inflammation
Rupert VesseyChief Scientist and Executive Partner

Board

DirectorRole
Noubar AfeyanChair of the Board
Frances ArnoldDirector
Jane MendilloDirector
Marsha FanucciDirector
Nancy SimonianDirector
Paul ParkerDirector
Rupert VesseyChief Scientist and Executive Partner
Stéphane BancelDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−6.8%
Q2 2026Aug 6, 2026 · Before open−4.1%
Q1 2026May 7, 2026 · Before open−11.2%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck56 slidesOctober 2026
Investor Presentation (October 2026)Investor deck57 slidesOctober 2026
Investor Presentation (October 2026)Investor deck55 slidesOctober 2026
Investor Presentation (June 2026)Investor deck51 slidesJune 2026
ERS Congress 2025 (Late Breaker)Conference11 slides2025
IDWeek 2024Conference12 slidesOctober 2024

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: US$400M · US$16 a share · Goldman Sachs & Co. LLC +4
Dealers: Goldman Sachs & Co. LLC (co-lead), Morgan Stanley (co-lead), Piper Sandler, Guggenheim Securities, Cantor
Feb 27, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Feb 26, 2026.

Price
US$16.00 a share
Shares offered
25,000,000 shares of common stock
Offering size
US$400 million
Underwriters' option
Up to 3,750,000 more shares
Listing
GENB on the Nasdaq Global Select Market
Underwriters
Goldman Sachs & Co. LLC, Morgan Stanley, Piper Sandler, Guggenheim Securities, Cantor · In the order on the cover
Shares delivered
On or about Mar 2, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceDec 23, 2025
Filed publiclyFeb 4, 2026
Amended twiceNewest Feb 23, 2026
Shares registered with an exchangeFeb 24, 2026
Declared effective by the SECFeb 26, 2026
Final prospectus, with the priceFeb 27, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Feb 27, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue31.9M20.5M
Gross profit31.9M20.5M
Research and development224.7M175.3M
Selling, general and administrative42.3M42.1M
Operating income-235.1M-196.9M
Depreciation and amortization13.2M15.3M
EBITDA-221.9M-181.6M
Interest expense1.14M2.12M
Income before tax-222.8M-181.2M
Income tax163.0K212.0K
Net income-203.2M-173.8M
Earnings per share, basic-4.06-1.36

Balance sheet

LineFY2025FY2024
Cash and equivalents121.7M176.3M
Short-term investments99.8M217.4M
Receivables0308.0K
Current assets234.4M407.5M
Total assets330.2M518.3M
Accounts payable3.84M5.67M
Current liabilities82.2M86.6M
Total debt68.5M77.0M
Total liabilities953.4M953.3M
Shareholders' equity-616.0M-434.5M
Shares outstanding50.1M127.5M

Cash flow

LineFY2025FY2024
Cash from operations-200.6M-117.8M
Capital spending-3.51M-3.45M
Free cash flow-204.1M-121.2M
Cash from investing116.8M-57.7M
Cash from financing28.1M91.3M
Change in cash-55.8M-84.1M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeNov 5, 2026Big-stake noticeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
144 · Notice of proposed saleOct 29, 2026Other filingsSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
8-K · Current reportAug 25, 2026Current reportSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
All 58 filings
FilingDateTypeFiled with
8-K · Current reportAug 6, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
3 · Initial statement of ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
8-K · Current reportMar 2, 2026Current reportSEC
S-8 · Registration statement for employee plansFeb 27, 2026Offer documentSEC
424B4 · ProspectusFeb 27, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 27, 2026Other filingsSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
CERT · Exchange's certificate of listingFeb 26, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeFeb 24, 2026Other filingsSEC
S-1/A · Registration statement, amendedFeb 23, 2026Offer documentSEC
S-1/A · Registration statement, amendedFeb 13, 2026Offer documentSEC
S-1 · Registration statementFeb 4, 2026Offer documentSEC
DRS · Draft registration statementDec 23, 2025Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Generate Biomedicines, Inc.’s releases · as of Sep 30, 2026

Common shares
128,352,436
Fully diluted
128,352,436

Fully diluted

LineSharesAs of
Common shares128,352,436Sep 30, 2026

Share count over time

CountShares
Nov 22, 2026128,352,436
Sep 30, 2026129,021,869

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Flagship Pioneering, LLC62.7M48.5%US$941MSep 30, 2026
Fidelity7.19M5.6%US$108MSep 30, 2026
Capital Group4.2M3.3%US$63.1MSep 30, 2026
Braidwell LP2.96M2.3%US$44.5MSep 30, 2026
JPMorgan2.65M2.1%US$40.9MSep 30, 2026
Vanguard2.62M2.0%US$39.3MSep 30, 2026
Deep Track Capital, LP2.51M1.9%US$37.7MSep 30, 2026
ARK1.96M1.5%US$29.5MSep 30, 2026
ARCH Venture Management, LLC1.94M1.5%US$29.2MSep 30, 2026
BlackRock1.83M1.4%US$27.5MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Banque Pictet & Cie SA1.77M1.4%US$26.6MSep 30, 2026
HarbourVest Partners LLC1.72M1.3%US$25.9MSep 30, 2026
Baker Bros. Advisors LP1.42M1.1%US$21.4MSep 30, 2026
T. Rowe Price1.34M1.0%US$20.1MSep 30, 2026
ArrowMark Colorado Holdings LLC1.11M0.86%US$16.7MSep 30, 2026
Nvidia Corp833K0.65%US$12.5MSep 30, 2026
Davern Capital Partners, LP825K0.64%US$12.4MSep 30, 2026
Siren, L.L.C.736K0.57%US$11.1MSep 30, 2026
Geode Capital729K0.56%US$11MSep 30, 2026
State Street546K0.42%US$8.21MSep 30, 2026
Millennium542K0.42%US$8.14MSep 30, 2026
Morgan Stanley522K0.40%US$7.85MSep 30, 2026
Voloridge Investment Management, LLC362K0.28%US$5.44MSep 30, 2026
Schwab237K0.18%US$3.57MSep 30, 2026
Two Sigma205K0.16%US$3.08MSep 30, 2026
Northern Trust193K0.15%US$2.9MSep 30, 2026
TD181K0.14%US$2.78MSep 30, 2026
Alps Advisors Inc170K0.13%US$2.55MSep 30, 2026
Goldman Sachs146K0.11%US$2.19MSep 30, 2026
Prosight Management, LP145K0.11%US$2.17MSep 30, 2026
Savant Capital, LLC139K0.11%US$2.09MSep 30, 2026
UBS127K0.10%US$1.91MSep 30, 2026
LMR Partners LLP126K0.10%US$1.89MSep 30, 2026
Seven Grand Managers, LLC125K0.10%US$1.88MSep 30, 2026
Quadrature Capital Ltd120K0.09%US$1.81MSep 30, 2026
Barclays118K0.09%US$1.78MSep 30, 2026
Manufacturers Life Insurance Company, The116K0.09%US$1.74MSep 30, 2026
Affinity Asset Advisors, LLC100K0.08%US$1.5MSep 30, 2026
Ameriprise85,5670.07%US$1.29MSep 30, 2026
Nuveen85,2810.07%US$1.28MSep 30, 2026
IQ EQ FUND MANAGEMENT (IRELAND) Ltd84,9590.07%US$1.28MSep 30, 2026
Gsa Capital Partners LLP81,6180.06%US$1.23MSep 30, 2026
Amova Asset Management Americas, Inc.78,5310.06%US$1.18MSep 30, 2026
Sumitomo Mitsui Trust Group, Inc.78,5310.06%US$1.18MSep 30, 2026
Bank Pictet & Cie (Europe) AG77,7780.06%US$1.17MSep 30, 2026
BNP Paribas62,5200.05%US$939KSep 30, 2026
Aquatic Capital Management LLC60,1580.05%US$904KSep 30, 2026
BNY59,3640.05%US$892KSep 30, 2026
XTX Topco Ltd51,7620.04%US$777KSep 30, 2026
Susquehanna45,4450.04%US$683KSep 30, 2026

This page holds 50 of 104 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
SMALLCAP World Fund Inc3.75M2.9%US$63.3MJun 30, 2026
ARK Genomic Revolution ETF1.24M0.96%US$17.3MJul 31, 2026
Vanguard Total Stock Market Index Fund817K0.63%US$13.8MJun 30, 2026
Fidelity Growth Company Fund635K0.49%US$8.33MMay 31, 2026
iShares Russell 2000 ETF618K0.48%US$10.4MJun 30, 2026
JPMorgan Small Cap Growth Fund580K0.45%US$9.79MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.315K0.24%US$5.31MJun 30, 2026
Eaton Vance Worldwide Health Sciences Fund313K0.24%US$4.1MMay 31, 2026
Vanguard Extended Market Index Fund296K0.23%US$5MJun 30, 2026
Fidelity Small Cap Index Fund267K0.21%US$3.74MJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
JPMorgan Small Cap Blend Fund184K0.14%US$3.11MJun 30, 2026
Fidelity Growth Company K6 Fund177K0.14%US$2.33MMay 31, 2026
American Funds U.S. Small & Mid Cap Equity Fund174K0.14%US$2.29MMay 31, 2026
Fidelity Series Growth Company Fund169K0.13%US$2.22MMay 31, 2026
iShares Russell 2000 Growth ETF158K0.12%US$2.66MJun 30, 2026
SMALLCAP World Fund104K0.08%US$1.75MJun 30, 2026
Multi-Manager Small Cap Equity Strategies Fund91,9640.07%US$1.21MMay 31, 2026
Fidelity Nasdaq Composite Index Fund77,0690.06%US$1.01MMay 31, 2026
iShares Russell 2000 Value ETF66,0870.05%US$1.11MJun 30, 2026
JPMorgan U.S. Small Company Fund59,6160.05%US$1.01MJun 30, 2026
Schwab Small-Cap Index Fund59,2310.05%US$829KJul 31, 2026
Small Cap Value Fund53,1860.04%US$698KMay 31, 2026
Master Small Cap Index Series45,6330.04%US$770KJun 30, 2026
Fidelity Nasdaq Composite Index ETF41,8540.03%US$549KMay 31, 2026
Nuveen Small Cap Blend Index Fund32,3820.03%US$453KJul 31, 2026
U.S. Small and Mid Cap Equity Fund26,8420.02%US$453KJun 30, 2026
EQ/2000 Managed Volatility Portfolio26,1250.02%US$441KJun 30, 2026
Schwab Total Stock Market Index Fund25,5920.02%US$358KJul 31, 2026
Virtus Biotech Clinical Trials Etf25,1060.02%US$351KJul 31, 2026
Select Biotechnology Portfolio21,8000.02%US$286KMay 31, 2026
Health Sciences Trust19,2770.01%US$325KJun 30, 2026
T. Rowe Price Health Sciences Portfolio19,1150.01%US$322KJun 30, 2026
LVIP State Street Small-Cap Index Fund17,7000.01%US$299KJun 30, 2026
Blackstone Alternative Multi-Strategy Fund16,4380.01%US$277KJun 30, 2026
Fidelity Small Cap Growth Index Fund15,7240.01%US$265KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund14,8890.01%US$251KJun 30, 2026
EQ/T.Rowe Price Health Sciences Portfolio13,4530.01%US$227KJun 30, 2026
LVIP JPMorgan Small Cap Core Fund13,3040.01%US$224KJun 30, 2026
Small Cap Index Fund12,605<0.01%US$213KJun 30, 2026
Global X Russell 2000 ETF11,616<0.01%US$163KJul 31, 2026
Fidelity Small Cap Value Index Fund10,571<0.01%US$178KJun 30, 2026
EQ/Small Company Index Portfolio9,550<0.01%US$161KJun 30, 2026
EQ/AB Small Cap Growth Portfolio9,550<0.01%US$161KJun 30, 2026
Tiff Multi-Asset Fund9,229<0.01%US$156KJun 30, 2026
ATM Small Cap Managed Volatility Portfolio8,949<0.01%US$151KJun 30, 2026
Vy(R) Jpmorgan Small Cap Core Equity Portfolio8,757<0.01%US$148KJun 30, 2026
MetLife Russell 2000 Index Portfolio8,412<0.01%US$142KJun 30, 2026
Small-Cap Index Portfolio6,910<0.01%US$117KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio6,800<0.01%US$115KJun 30, 2026
Victory Extended Market Index Fund6,300<0.01%US$88,200Jul 31, 2026

This page holds 50 of 89 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Arnold Frances
Director
Sale11,409USD 16.19US$185KOct 29, 2026
Arnold Frances
Director
Sale1,000USD 16.00US$16,000Sep 1, 2026

Big stakes

StakeStakeSharesDateFiling
Flagship Pioneering, LLC48.90%62.7MMar 31, 2026Schedule 13G
FMR LLC5.60%7.19MSep 30, 2026Schedule 13G
Nally Michael5.20%6.92MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Noubar Afeyan
Other companies: Foghorn Therapeutics Inc. (Director · Since at least Jan 13, 2026); Moderna, Inc. (Director · Since at least Dec 7, 2018); BG Medicine Inc (Director · Since at least Feb 3, 2011); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Mar 4, 2019 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 12, 2019 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 21, 2016 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 18, 2019 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – Mar 20, 2014 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Sep 25, 2013 · Past); Color Kinetics Inc (Director · Jan 3, 2006 – Aug 24, 2007 · Past); Agenus Inc. (Director · Jan 13, 2005 – Jun 7, 2007 · Past)
Chair of the Board · Since at least Feb 26, 2026
Marsha Fanucci
Other companies: Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Oct 14, 2022 · Past); Cyclerion Therapeutics, Inc. (Director · Mar 14, 2019 – Jun 14, 2022 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 5, 2024 · Past); Alnylam Pharmaceuticals, Inc. (Director · Dec 8, 2010 – May 18, 2023 · Past); Ironwood Pharmaceuticals, Inc. (Director · Feb 2, 2010 – Apr 1, 2019 · Past); Momenta Pharmaceuticals Inc (Director · Jun 15, 2006 – Jun 23, 2016 · Past); Millennium Pharmaceuticals Inc (SVP, Chief Financial Officer · Sep 15, 2005 – May 14, 2008 · Past)
Director · Since at least Feb 26, 2026
Nancy Simonian
Other companies: Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 17, 2020 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Dec 2, 2024 · Past); Seagen Inc (Director · Mar 19, 2012 – Dec 14, 2023 · Past); Millennium Pharmaceuticals Inc (Chief Medical Officer · May 31, 2007 – May 14, 2008 · Past); ArQule Inc (Director · May 12, 2006 – May 13, 2010 · Past)
Director · Since at least Feb 26, 2026
Frances Arnold
Other companies: Alphabet Inc (Google) Class C (Director · Since at least Dec 31, 2020); Illumina, Inc. (Director · Dec 23, 2020 – May 21, 2025 · Past)
Director · Since at least Feb 26, 2026
Jane Mendillo
Other companies: General Motors Company (Director · Jun 7, 2016 – Dec 31, 2021 · Past); Lazard, Inc. (Director · Apr 19, 2016 – Feb 18, 2025 · Past)
Director · Since at least Feb 26, 2026
Michael Nally
Other companies: PPG Industries, Inc. (Director · Since at least Feb 18, 2021); Merck & Company, Inc. (EVP, Chief Marketing Officer · Jan 1, 2019 – Feb 26, 2021 · Past)
Chief Executive Officer, Director · Since at least Feb 26, 2026
Rupert Vessey
Other companies: Bio-Techne Corp (Director · Since at least Oct 29, 2020); Bristol-Myers Squibb Company (EVP & President, Research · Oct 30, 2020 – May 3, 2023 · Past)
Director · Since at least Feb 26, 2026
Sean Martin
Other companies: Baxter International Inc. (SVP and General Counsel · Feb 28, 2017 – Mar 2, 2022 · Past); Apollo Education Group Inc (SVP, General Counsel · Sep 23, 2010 – Feb 1, 2017 · Past)
Chief Legal Officer & General Counsel · Since at least Feb 26, 2026
Stéphane Bancel
Other companies: BG Medicine Inc (Executive Chairman of the Board · Since at least Nov 5, 2026); Moderna, Inc. (Chief Executive Officer, Director · Since at least Aug 5, 2026)
Director · Since at least Nov 4, 2026
Paul Parker
Other companies: Clorox Company (the) (Director · Nov 18, 2020 – Sep 30, 2024 · Past)
Director · Since at least Feb 26, 2026
All 19 people
PersonSeat
Aarif KhakooChief Scientific Officer · Since at least Feb 26, 2026
Beth GrousChief People Officer · Since at least Feb 26, 2026
Beth GrousChief People Officer · Since at least Nov 4, 2026
Daria HazudaSenior Vice President, Discovery Strategy · Since at least Nov 4, 2026
Dinesh de AlwisSenior Vice President, Head of Clinical Drug Development · Since at least Oct 1, 2026
Gevorg GrigoryanCo-Founder & Chief Technology Officer · Since at least Feb 26, 2026
Jason SilversPresident & CFO · Since at least Feb 26, 2026
Laurie LeeChief Medical Officer, Immunology & Inflammation · Since at least Feb 26, 2026
Sahm NasseriSenior Vice President, Business Development and Strategy · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Generate Biomedicines, Inc.